IL-2R alpha (CD25), Human Antibody

ZZZZ_Status (Active, Disc) : Active

AA_Supplier Name : Biosensis

Alternative_Name (Other Names) :

Interleukin-2 receptor subunit alpha; IL-2 receptor subunit alpha; IL-2R subunit alpha; IL-2-RA; IL2-RA; TAC antigen; p55; CD25.

Antibody_Isotype
(Antibody only) : IgG1kappa

Application_Details :

Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1κ constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.

Background_Info :

Clone_Name
(AB only, monoclonals) : Basiliximab

Datasheet_Link :

Description (Long Description) : 

NOT FOR THERAPEUTIC USE – This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1κ constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.

Expiry_Date : 

12 months after purchase if unopened.

Format (Form) : 

Liquid, PBS with 0.02% Proclin 300.

Immunogen (Antigen) :Basiliximab was prepared by immunizing BALB/c mice with CTC 16 cells.

Kit_Components :

MSDS (File name) :